CoChat

miR-34 miRNAs Regulate Cellular Senescence in Type II Alveolar Epithelial Cells of Patients with Idiopathic Pulmonary Fibrosis

Open access

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Pathologic features of idiopathic pulmonary fibrosis (IPF) include genetic predisposition, activation of the unfolded protein response, telomere attrition, and cellular senescence. The mechanisms leading to alveolar epithelial cell (AEC) senescence are poorly understood. MicroRNAs (miRNAs) have been reported as regulators of cellular senescence. Senescence markers including p16, p21, p53, and senescence-associated β-galactosidase (SA-βgal) activity were measured in type II AECs from IPF lungs and unused donor lungs. miRNAs were quantified in type II AECs using gene expression arrays and quantitative RT-PCR. Molecular markers of senescence (p16, p21, and p53) were elevated in IPF type II AECs. SA-βgal activity was detected in a greater percentage in type II AECs isolated from IPF patients (23.1%) compared to patients with other interstitial lung diseases (1.2%) or normal controls (0.8%). The relative levels of senescence-associated miRNAs miR-34a, miR-34b, and miR-34c, but not miR-20a, miR-29c, or miR-let-7f were significantly higher in type II AECs from IPF patients. Overexpression of miR-34a, miR-34b, or miR-34c in lung epithelial cells was associated with higher SA-βgal activity (27.8%, 35.1%, and 38.2%, respectively) relative to control treated cells (8.8%). Targets of miR-34 miRNAs, including E2F1, c-Myc, and cyclin E2, were lower in IPF type II AECs. These results show that markers of senescence are uniquely elevated in IPF type II AECs and suggest that the miR-34 family of miRNAs regulate senescence in IPF type II AECs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0158367

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Lung staining for SA-β-galactosidase activity. (A and B) 5 μM sections of lung from of patients with IPF, (C) normal donor controls, (D) scleroderma, or (E) hypersensitivity pneumonitis were stained for SA-βgal activity. Note the blue staining epithelial cells in IPF lung (A and B, arrows) but not normal individuals, or patients with scleroderma or hypersensitivity pneumonitis. Images are representative of staining of tissue from 8 patients with IPF, 14 control subjects, 5 patients with scleroderma, and 8 patients with hypersensitivity pneumonitis.
Fig 1 Lung staining for SA-β-galactosidase activity. (A and B) 5 μM sections of lung from of patients with IPF, (C) normal donor controls, (D) scleroderma, or (E) hypersensitivity pneumonitis were stained for SA-βgal activity. Note the blue staining epithelial cells in IPF lung (A and B, arrows) but not normal individuals, or patients with scleroderma or hypersensitivity pneumonitis. Images are representative of staining of tissue from 8 patients with IPF, 14 control subjects, 5 patients with scleroderma, and 8 patients with hypersensitivity pneumonitis.CC0 · PubMed Central
Fig 2 Immunohistochemistry of IPF and normal lung with p16, p21, or p53 antibodies. 5 μM sections of normal lung immunostained for (A) p16, (B) p21, (C) p53 show an absence of staining. In contrast, IPF lung immunostained for (D) p16, (E) p21, or (F) p53 show immunoreactive cells lining airspaces consistent with type II AECs. (G-I) Isotype control for p16, p21, or p53 are shown. Images are representative of staining of tissue from 12 patients with IPF and 10 control subjects.
Fig 2 Immunohistochemistry of IPF and normal lung with p16, p21, or p53 antibodies. 5 μM sections of normal lung immunostained for (A) p16, (B) p21, (C) p53 show an absence of staining. In contrast, IPF lung immunostained for (D) p16, (E) p21, or (F) p53 show immunoreactive cells lining airspaces consistent with type II AECs. (G-I) Isotype control for p16, p21, or p53 are shown. Images are representative of staining of tissue from 12 patients with IPF and 10 control subjects.CC0 · PubMed Central
Fig 3 Expression of senescence markers in isolated type II AECs. (A) Immunoblot for p16, p21 and p53 shows higher levels of these proteins in type II AECs isolated from IPF patients relative to those from control subjects. Relative densitometric ratios of p16, p21, and p53 to β-actin are presented by bar graphs (* p < 0.05). (B) SA-βgal activity in type II AECs isolated from IPF lungs was detected in an average of 23.1 ± 13% of cells relative to type II AECs isolated from disease controls (1.2 ± 1.3%), control subjects (0.8 ± 0.6%) and unstatined type II AECs (1.5 ± 0.7%). (C) Scatter plots of age and SA-βgal activity of patients whose type II AECs were analyzed by flow cytometry.
Fig 3 Expression of senescence markers in isolated type II AECs. (A) Immunoblot for p16, p21 and p53 shows higher levels of these proteins in type II AECs isolated from IPF patients relative to those from control subjects. Relative densitometric ratios of p16, p21, and p53 to β-actin are presented by bar graphs (* p < 0.05). (B) SA-βgal activity in type II AECs isolated from IPF lungs was detected in an average of 23.1 ± 13% of cells relative to type II AECs isolated from disease controls (1.2 ± 1.3%), control subjects (0.8 ± 0.6%) and unstatined type II AECs (1.5 ± 0.7%). (C) Scatter plots of age and SA-βgal activity of patients whose type II AECs were analyzed by flow cytometry.CC0 · PubMed Central
Fig 4 qRT-PCR for miRNAs isolated from type II AECs. Box plots of normalized relative log2 expression of miRNAs in type II AECs isolated from IPF patients (n = 15) and control subjects (n = 15). The levels of miR-34a (A), miR-34b (B), and miR-34c (C) were significantly higher in type II AECs isolated from IPF patients compared to those from control subjects (* p< 0.001 by Mann-Whitney U test). The levels of (D) miR-20a, (E) miR-29c, and (F) miR-let-7f were not significantly different in IPF patients relative to control subjects. The boxes are drawn extending from the 75th percentile to the 25th percentile. The horizontal line inside the box represents median values. The whiskers above and below the box delineate the maximum and minimum.
Fig 4 qRT-PCR for miRNAs isolated from type II AECs. Box plots of normalized relative log2 expression of miRNAs in type II AECs isolated from IPF patients (n = 15) and control subjects (n = 15). The levels of miR-34a (A), miR-34b (B), and miR-34c (C) were significantly higher in type II AECs isolated from IPF patients compared to those from control subjects (* p< 0.001 by Mann-Whitney U test). The levels of (D) miR-20a, (E) miR-29c, and (F) miR-let-7f were not significantly different in IPF patients relative to control subjects. The boxes are drawn extending from the 75th percentile to the 25th percentile. The horizontal line inside the box represents median values. The whiskers above and below the box delineate the maximum and minimum.CC0 · PubMed Central
Fig 5 SA-βgal activity detected by flow cytometry in A549 cells overexpressing miR-34a, miR-34b, and miR-34c. The relative percentage of cells with detectable SA-gal activity was measured in A549 cells overexpressing (A) miR-34a, (B) miR-34b, (C) miR-34c, or (D) mCherry control. Note the higher percentage of cells with SA-βgal activity in cells overexpressing miR-34a, miR-34b, or miR-34c compared to treated control cells.
Fig 5 SA-βgal activity detected by flow cytometry in A549 cells overexpressing miR-34a, miR-34b, and miR-34c. The relative percentage of cells with detectable SA-gal activity was measured in A549 cells overexpressing (A) miR-34a, (B) miR-34b, (C) miR-34c, or (D) mCherry control. Note the higher percentage of cells with SA-βgal activity in cells overexpressing miR-34a, miR-34b, or miR-34c compared to treated control cells.CC0 · PubMed Central
Fig 6 Targets of miR-34 family in isolated type II AECs and A549 cells overexpressing miR-34 family miRNAs. (A-F) Box plots of normalized relative log2 expression of SIRT1, E2F1, c-Myc, CDK4, CDK6, and CCNE2 in type II AECs isolated from IPF patients (n = 15) and control subjects (n = 15). The expression levels of (B) E2F1, (C) c-Myc, and (F) CCNE2 were significantly lower in type II AECs isolated from IPF patients compared to those from control subjects (* p < 0.05 by Mann-Whitney U test). The boxes are drawn extending from the 75th percentile to the 25th percentile. The horizontal line inside the box represents median values. The whiskers above and below the box delineate the maximum and minimum. (G) Expression levels of candidate targets of miR-34 family were also measured in A549 overexpressing miR-34a, miR-34b, or miR-34c by qRT-PCR.
Fig 6 Targets of miR-34 family in isolated type II AECs and A549 cells overexpressing miR-34 family miRNAs. (A-F) Box plots of normalized relative log2 expression of SIRT1, E2F1, c-Myc, CDK4, CDK6, and CCNE2 in type II AECs isolated from IPF patients (n = 15) and control subjects (n = 15). The expression levels of (B) E2F1, (C) c-Myc, and (F) CCNE2 were significantly lower in type II AECs isolated from IPF patients compared to those from control subjects (* p < 0.05 by Mann-Whitney U test). The boxes are drawn extending from the 75th percentile to the 25th percentile. The horizontal line inside the box represents median values. The whiskers above and below the box delineate the maximum and minimum. (G) Expression levels of candidate targets of miR-34 family were also measured in A549 overexpressing miR-34a, miR-34b, or miR-34c by qRT-PCR.CC0 · PubMed Central
Fig 7 Proposed relationship between miR-34 miRNAs and their targets as mediators of cellular senescence in IPF type II AECs. p53 activation leads to up-regulation of miR-34 family of miRNAs in IPF type II AECs. Elevated miR-34a, miR-34b, or miR-34c levels lead to down-regulation of key target genes, including E2F1, c-Myc, and CCNE2, involved in the cell cycle, leading to cellular senescence.
Fig 7 Proposed relationship between miR-34 miRNAs and their targets as mediators of cellular senescence in IPF type II AECs. p53 activation leads to up-regulation of miR-34 family of miRNAs in IPF type II AECs. Elevated miR-34a, miR-34b, or miR-34c levels lead to down-regulation of key target genes, including E2F1, c-Myc, and CCNE2, involved in the cell cycle, leading to cellular senescence.CC0 · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 140

Metadata

Authors
Disayabutr, S., Kim, E. K., Cha, S.-I., Green, G., Naikawadi, R. P., Jones, K. D., Golden, J. A., Schroeder, A., Matthay, M. A., Kukreja, J., Erle, D. J., Collard, H. R., & Wolters, P. J.
Affiliations
University of California, San Francisco (US)
Corresponding author
Wolters, Paul J.
Venue
PLOS ONE
Published
2016-06-30
Volume
11
Issue
6
Pages
e0158367
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2463253169
Cited by
136
References
54
Citations by year
2026: 6 · 2025: 7 · 2024: 13 · 2023: 9 · 2022: 12 · 2021: 17 · 2020: 18 · 2019: 12 · 2018: 17 · 2017: 22 · 2016: 2
FWCI
15.80
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, public-domain)
  • Europe PMC (PubMed Central) (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Institutes of Health
  • Nina Ireland Program in Lung Health
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
Keywords
idiopathic pulmonary fibrosis, cellular senescence, alveolar type II cells, miR-34 family, microRNA, senescence-associated β-galactosidase, p16, p21, p53, E2F1, c-Myc, cyclin E2, unfolded protein response, telomere shortening
MeSH terms
A549 Cells, Gene Expression Regulation, Humans, Lung, Biomarkers, Case-Control Studies, Cellular Senescence, Disease Progression, Gene Expression Profiling, MicroRNAs, Microarray Analysis, Idiopathic Pulmonary Fibrosis, Alveolar Epithelial Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.